Full text is available at the source.
Abstract
Urolithin A (UA) is recognized as a postbiotic treatment that may influence mitochondrial pathways and gut microbiome interactions.
- UA is produced when the body metabolizes ellagic acid and ellagitannins.
- The gut microbiota is linked to metabolic regulators, which are important for intestinal health and inflammation reduction.
- Preclinical studies suggest that UA may alter cancer cell metabolism and reinforce the intestinal barrier.
- UA is associated with enhanced muscle endurance and improved indicators of mitochondrial function.
- Preliminary human trials indicate UA could support cardiometabolic health without adverse effects, particularly in elderly and sedentary individuals.
- Variability in UA production is noted due to differences in gut flora, highlighting the need for more comprehensive clinical trials.
Simplified